• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Advanced Enzyme Technologies Ltd.
    05 Aug 2025
    Broker's call: Advanced Enzyme (Buy)
    Business Line
    Centrum Broking
    Copy LinkShare onShare on Share on Share on
    Advanced Enzyme Technologies Ltd. has lost -26.87% in the last 1 Year
    logo
    Alembic Pharmaceuticals Ltd.
    05 Aug 2025
    USFDA Approval Insider Trades
    947.15
    -0.50%
    Alembic Pharmaceuticals first-quarter profit jumps to 154.27 on strong US, domestic sales
    Business Line
    India's generic drugmakers have been facing margin pressures due to lower prices in the US amid fierce competition
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr
    logo
    Aurobindo Pharma Ltd.
    05 Aug 2025
    US FDA Observation High Gain High Volume
    1109.20
    5.61%
    Aurobindo Pharma stock falls 2% after Q1 results; check key numbers here
    Business Standard
    Aurobindo Pharma's net profit fell 10.2 per cent Y-o-Y to 824 crore in Q1FY26, as against 918 crore in the same quarter last year
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.
    Aurobindo Pharma Q1 PAT falls 10% on drop in API sales, US market revenue
    Business Standard | 05 Aug 2025 4 more
    Aurobindo Pharma Q1 results: Profit drops 10% to 824 crore on US sales
    Business Standard | 04 Aug 2025
    Aurobindo Pharma's Q1 net down 10.2% at 824 cr
    Business Line | 04 Aug 2025
    Aurobindo Pharma Declares Dividend Of Rs 4 Check Record Date, Details
    NDTV Profit | 04 Aug 2025
    Aurobindo Pharma Q1 Results: Profit Falls 10%, Misses Estimates
    NDTV Profit | 04 Aug 2025
    logo
    Sanofi Consumer Healthcare India Ltd.
    04 Aug 2025
    5161.00
    0.46%
    Sanofi Consumer Healthcare Q2 - driven by exports, product launches
    Business Line
    Quarter and half-year financials are not directly comparable due to the demerger and voluntary recall of certain variants of key brands, the company said
    Copy LinkShare onShare on Share on Share on
    Institutional Investors have decreased holdings from 30.00% to 20.13% in Jun 2025 qtr
    logo
    Emcure Pharmaceuticals Ltd.
    04 Aug 2025
    1376.70
    1.06%
    Emcure Pharma shares gain as JM Financial initiates coverage; check target
    Business Standard
    JM Financial initiated coverage on Emcure Pharma with a 'Buy' rating and a target price of 1,740, citing its growth prospects
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. is trading below its 30 day SMA of 1416.0
    logo
    Dr. Reddy's Laboratories Ltd.
    04 Aug 2025
    US FDA Observation Acquisition
    1303.10
    -0.08%
    Dr. Reddy's Laboratories Price Target Cut By Citi Over Intensifying Generic Competition Full Details
    Dr. Reddy's Laboratories Price Target Cut By Citi Over Intensifying Generic Competition Full Details
    NDTV Profit
    Citi notes that market expectations for Dr. Reddy's Semaglutide opportunity may be too optimistic.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.
    logo
    GlaxoSmithKline Pharmaceuticals Ltd.
    01 Aug 2025
    2863.80
    0.93%
    GSK Pharma on track to bring in its oncology products Jemperli and Zejula
    Business Line
    Bhushan Akshikar, GSK Pharma Managing Director said the company would invest in its innovative portfolio and was on track to launch its oncology assets, Jemperli (dostarlimab) and Zejula (niraparib)
    Copy LinkShare onShare on Share on Share on
    GlaxoSmithKline Phar.. has an average target of 2800.00 from 2 brokers.
    GSK Pharma Q1 results: PAT rises 12% to 279 cr, income declines marginally
    Business Standard | 01 Aug 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    01 Aug 2025
    US FDA Classification
    1609.70
    1.02%
    Broker's call: Sun Pharma (Outperform)
    Business Line
    BNP Paribas
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading below all available SMAs
    Sun Pharma shares drop nearly 6% after Q1 earnings
    Business Line | 01 Aug 2025 7 more
    Sun Pharma Shares Decline Over 5% As Q1 Profit Falls 20%
    NDTV Profit | 01 Aug 2025
    Sun Pharma Q1 Review Dolat Capital Maintains 'Reduce', Sees Current Valuations To Limit Upside
    NDTV Profit | 01 Aug 2025
    Sun Pharma Q1 net profit falls 20% Y-o-Y; revenue rises 9%
    Business Standard | 31 Jul 2025
    Sun Pharma has no plans to shift manufacturing to US, says management
    Business Line | 31 Jul 2025
    Sun Pharma Q1 results: PAT dips 20% to 2,279 crore; revenue rises 8.6%
    Business Standard | 31 Jul 2025
    Sun Pharmaceutical Q1 Results: Profit Falls 20% As Exceptional Loss Weighs
    NDTV Profit | 31 Jul 2025
    Sun Pharma Q1 Results: Cons profit falls 20% YoY to Rs 2,278 crore, but revenue rises 10%
    Economic Times | 31 Jul 2025
    logo
    J B Chemicals & Pharmaceuticals Ltd.
    01 Aug 2025
    Insider Trades
    1705.50
    -0.25%
    'Buy' JB Chemicals Maintains PL Capital Post Q1 Results Check Target Price
    'Buy' JB Chemicals Maintains PL Capital Post Q1 Results Check Target Price
    NDTV Profit
    JB Chemicals' margins will continue to improve beyond FY27 with grant of perpetual license of acquired opthal portfolio.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 319 to 311 in Jun 2025 qtr
    logo
    Gland Pharma Ltd.
    01 Aug 2025
    1965.80
    3.33%
    US tariffs call for strategic agility, cost discipline to ensure growth: Gland Pharma Executive Chairman Srinivas Sadu
    Business Line
    Gland Pharma is open to explore strategic M&As to access new technologies, diversify portfolio
    Copy LinkShare onShare on Share on Share on
    Gland Pharma Ltd. is trading above all available SMAs
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd